Inflammatory pathway proteins (N/A)

Inflammatory pathway proteins represent a diverse group of molecular entities, including cytokines, chemokines, enzymes, and transcription factors, that orchestrate the body's response to harmful stimuli such as pathogens or tissue damage (StatPearls, 2023). Key members of this group include Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), and Janus Kinases (JAK), which serve as critical nodes in signaling cascades like the NF-kappaB and JAK-STAT pathways (NIH, 2022). In healthy states, these proteins facilitate the recruitment of immune cells and the resolution of injury; however, their chronic overactivation is a primary driver of autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel disease, as well as systemic conditions like sepsis (Nature Reviews Immunology, 2021). Pharmacological intervention typically involves monoclonal antibodies that neutralize specific cytokines or small molecules that inhibit intracellular signaling enzymes to restore immune homeostasis (PubMed, 2020). Because these proteins are integral to host defense, therapeutic modulation carries risks of immunosuppression and opportunistic infections (FDA, 2023).

Other names

Pro-inflammatory mediatorsInflammatory signaling moleculesInflammatory cytokines and enzymes

Inhibition of pro-inflammatory cytokine activity, blockade of cytokine receptors, or inhibition of intracellular signaling kinases to reduce the production and effect of inflammatory mediators (StatPearls, 2023).